For most of a decade, the answer to "can an insurance company merge with its own parent" was no, because there was nothing in the Insurance Act, 1938 to allow it. The Sabka Bima Sabki Raksha (Amendment of Insurance Laws) Act, 2025, in force from February 5, 2026, rewrote Section 35 to permit a scheme to amalgamate the non-insurance business of any company with the insurance business of an insurer, and Section 37 now refers to two or more entities rather than two or more insurers. IRDAI's amendments notified on July 30, 2026 turn that into a workable route, and the first structure built on it is Max Financial Services merging into Axis Max Life.

Context: what the rule allows and what it forbids

Regulation 30A is deliberately narrow. The transferor must be either an insurer or a company holding more than 50 percent of the insurer's paid-up equity capital, and at the date of the Section 35 application that holding company must carry on no non-insurance business beyond holding that insurer. The scheme must be prepared under Section 35.

Five conditions attach to the amalgamation. The policyholders' fund cannot be used at any time to meet any liability, claim or obligation arising out of it. The board of the transferee insurer must satisfy itself that the amalgamation will not adversely affect policyholders' interests. The transferee must demonstrate to IRDAI's satisfaction that solvency after the merger stays above the control level, and must comply with extant investment norms. And consideration has one permitted form only: equity shares of the transferee insurer issued to the transferor's shareholders, each of whom must meet the Fit and Proper criteria in Schedule 4. After the merger the insurer may carry on only the insurance business for which it holds a certificate of registration, and must keep policyholder interest protected at all times.

The same amendment rewrote the share-transfer approval thresholds, which now bite at 5, 10, 25, 50 and 75 percent and on becoming the single largest shareholder, catch transfers inside a group and dilution from declining a rights issue, and omit the old Regulation 25 route that allowed listed insurers to self-certify smaller transfers.

Implication: why the first approval matters more than the rule

  • It unwinds a decade of blockage, not a structure nobody wanted. IRDAI refused the earlier proposal in which Max Life would merge into its non-insurance parent and the combined entity would then merge with HDFC Life, on the ground that no enabling provision existed. A panel set up in February 2025 had also advised against such mergers on policyholder-risk grounds. The National Company Law Appellate Tribunal then held in IRDAI v. Shriram General Insurance that the absence of a statutory prohibition meant a scheme could be framed under the Companies Act without prior IRDAI approval. The new regulations accept that outcome and put the conditions back in the regulator's hands, which is the whole point.
  • It removes a holding-company discount without an initial public offering. Max Financial holds a majority of Axis Max Life and received in-principle board approval on January 28, 2026 to merge into its own subsidiary, with Max Financial's shareholders receiving Axis Max Life shares and the insurer listing directly. An upstream merger of this kind takes out the intermediate layer and can bring the operating business to listing, subject to minimum public shareholding, promoter classification and disclosure requirements.
  • It leaves out what the statute appears to allow. Mergers with operating group companies, combinations between sister entities, downstream mergers and multi-step schemes all fall outside Regulation 30A. The gap between Section 35 and 37 on one side and Regulation 30A on the other is the likely focus of the next round of representations, and the first approval under the rule will set the tone for how those gaps are read.
  • For a policyholder, the conditions are the protection, and they are testable. No policyholders' fund leakage, solvency above the control level, investment-norm compliance, and a board certificate that policyholders are not adversely affected are all things a regulator can examine. What a policyholder cannot do is treat the certificate as a conclusion: it is a board's view, and IRDAI's approval is the check on it.
  • There is one unresolved execution risk. The Fit and Proper criteria apply to shareholders of the transferor entity. For a company whose register is dispersed across retail investors, that test is impractical as literally written. The workable reading is that it is tested at the 5 percent threshold and for the promoter group, but IRDAI has not said so, and that ambiguity sits precisely in the transactions the rule was designed to enable.

Action

If you hold a policy with Axis Max Life, nothing about your cover changes because of a holding-company merger, and the conditions in the rule are written to keep it that way: the policyholders' fund cannot be used to fund the transaction and solvency must stay above the control level throughout. If you are an analyst or an investor in this space, the sequence to track is Section 35 application to IRDAI, IRDAI's prior approval, a scheme under Sections 230 to 232 of the Companies Act, sanction by the National Company Law Tribunal, and the scheme framework of the securities regulator if a listed entity is involved. Watch two things: whether IRDAI clarifies the Fit and Proper test for dispersed shareholders, and whether the first approved scheme completes, because a route nobody finishes is a route nobody uses.

Watch item: the separate rule that every insurer must add a word such as insurance or insurer to its corporate name within 12 months of July 30, 2026, after an IRDAI no-objection certificate. That is a governance signal about how the regulator is now treating corporate structure.